Harvard Business Review

MAY 10, 2016

For instance, despite the importance of accurately identifying and calculating company synergies, diligence work frequently results in an overly optimistic view of the revenue synergy opportunity. Often the weakest assumptions involve estimates of how much additional revenue the companies can generate when combined.

Biotech 14

Biotech Assets Revenue Marketing 14

Harvard Business Review

MARCH 1, 2012

But CMOs tend not to be favored by private investors, because these companies are asset heavy — they need land, buildings, equipment, vehicles, and large illiquid investment in capital equipment. Hence, by definition, they tend to have lower ROA, even if they have significant revenues and very high absolute profits.

Biotech 13

Biotech Assets Process Improvement Revenue 13

Harvard Business Review

AUGUST 17, 2015

Its current principal source of revenue is the export of healthcare services by means of sending physicians, nurses, and healthcare technicians to countries like Venezuela and Brazil—an item that it has yet to record in its published official statistics. We know two things about biotech in Cuba. So how does Cuba make money?

Government 15

Government Travel Assets Education 15